论文部分内容阅读
目的:探讨普米克令舒佐治小儿毛细支气管炎的临床疗效及安全性。方法:回顾性分析我院2014年3月-2015年3月收治的88例毛细支气管炎患儿的临床资料,将患儿随机分为观察组和对照组。对照组采用吸氧、抗炎、抗病毒、支气管扩张剂等常规治疗方法,观察组在对照组治疗基础上联合普米克令舒雾化吸入治疗,对比观察两组患儿的临床治疗效果。结果:观察组咳嗽停止时间、喘息停止时间、肺部哮鸣音消失时间、住院时间均比对照组短,观察组不良反应明显低于对照组,差异有统计学意义(P<0.05)。结论:小儿毛细支气管炎在常规治疗基础上采用普米克令舒雾化吸入可以明显提高治疗效果,不良反应少,缩短了患儿的治疗时间。
Objective: To investigate the clinical efficacy and safety of Pulmicort Respules pediatric bronchiolitis. Methods: The clinical data of 88 children with bronchiolitis admitted from March 2014 to March 2015 in our hospital were retrospectively analyzed. The children were randomly divided into observation group and control group. In the control group, conventional treatment such as oxygen inhalation, anti-inflammation, antivirus and bronchodilator were used. The observation group was treated with pulmicort inhalation based on the control group, and the clinical effect of the two groups was compared. Results: The cough stop time, wheezing stop time, disappearance time of lung wheeze and hospital stay in observation group were shorter than those in control group. The adverse reactions in observation group were significantly lower than those in control group (P <0.05). Conclusion: Pediatric bronchiolitis can improve the therapeutic effect obviously with the inhalation of pulmicort respules on the basis of routine treatment with less adverse reactions and shorten the treatment time of the children.